WHO Profits From the 'Parkinson's Pandemic'? Big Pharma's Billion-Dollar Miracle Cure Falls Short, Critics Cry Foul
As the global population ages, diagnosis of Parkinson's disease has skyrocketed—up 30% in the past decade alone—but newfound scrutiny reveals that the pharmaceutical giants pushing experimental gene therapies stand to reap billions from a condition they may be prolonging, not curing. Insider leaks claim a leading drug trial suppressed data showing worsening tremors in 40% of patients, while executives cashed in stock options before the report went public. From foundation-funded 'awareness campaigns' that double as marketing, to a new wave of 'dopamine-friendly' lifestyle apps that track data for insurers, skeptics ask: is the Parkinson's disease 'pandemic' a natural crisis, or a manufactured opportunity?